 Maki Nakayama
Concepts (174)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Antigen, T-Cell | 12 | 2023 | 632 | 3.240 |
Why?
| | Autoantigens | 12 | 2021 | 397 | 3.020 |
Why?
| | Insulin | 16 | 2021 | 2162 | 2.370 |
Why?
| | Protein Precursors | 4 | 2021 | 126 | 2.300 |
Why?
| | Diabetes Mellitus, Type 1 | 20 | 2023 | 3360 | 2.160 |
Why?
| | Islets of Langerhans | 9 | 2023 | 739 | 1.830 |
Why?
| | CD4-Positive T-Lymphocytes | 9 | 2021 | 984 | 1.780 |
Why?
| | T-Lymphocytes | 9 | 2023 | 1774 | 1.670 |
Why?
| | Epitopes | 4 | 2021 | 443 | 1.200 |
Why?
| | Peptide Fragments | 9 | 2019 | 702 | 1.200 |
Why?
| | Autoimmunity | 10 | 2022 | 831 | 0.930 |
Why?
| | Hybridomas | 5 | 2020 | 233 | 0.920 |
Why?
| | Proinsulin | 3 | 2016 | 48 | 0.900 |
Why?
| | CD3 Complex | 2 | 2020 | 92 | 0.890 |
Why?
| | Disease Susceptibility | 2 | 2021 | 331 | 0.870 |
Why?
| | Peptides | 4 | 2023 | 879 | 0.740 |
Why?
| | Lymphocyte Activation | 4 | 2020 | 1067 | 0.740 |
Why?
| | Retroviridae | 1 | 2020 | 89 | 0.730 |
Why?
| | Immunoassay | 1 | 2020 | 101 | 0.710 |
Why?
| | Immunomodulation | 1 | 2020 | 89 | 0.690 |
Why?
| | Insulin-Secreting Cells | 3 | 2019 | 330 | 0.690 |
Why?
| | Antigens | 2 | 2018 | 320 | 0.670 |
Why?
| | Cell Line, Transformed | 1 | 2018 | 136 | 0.650 |
Why?
| | Mice, Inbred NOD | 13 | 2019 | 574 | 0.630 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2018 | 68 | 0.610 |
Why?
| | Allografts | 1 | 2018 | 135 | 0.600 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2021 | 702 | 0.580 |
Why?
| | Graft Rejection | 1 | 2018 | 555 | 0.490 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 2012 | 310 | 0.450 |
Why?
| | Histocompatibility Antigens | 3 | 2021 | 102 | 0.450 |
Why?
| | Biomarkers | 2 | 2021 | 3588 | 0.410 |
Why?
| | Animals | 24 | 2022 | 33381 | 0.380 |
Why?
| | Macromolecular Substances | 1 | 2010 | 201 | 0.370 |
Why?
| | Mice | 19 | 2022 | 15520 | 0.370 |
Why?
| | Histocompatibility Antigens Class II | 4 | 2018 | 355 | 0.350 |
Why?
| | Urogenital Abnormalities | 2 | 2020 | 48 | 0.330 |
Why?
| | C-Peptide | 2 | 2018 | 137 | 0.290 |
Why?
| | Immunotherapy | 2 | 2021 | 493 | 0.280 |
Why?
| | Neoplasms | 1 | 2020 | 2179 | 0.270 |
Why?
| | Islet Amyloid Polypeptide | 2 | 2018 | 47 | 0.270 |
Why?
| | Amino Acid Substitution | 3 | 2020 | 276 | 0.270 |
Why?
| | Protein Binding | 5 | 2021 | 1975 | 0.270 |
Why?
| | Autoantibodies | 3 | 2010 | 1335 | 0.250 |
Why?
| | Alanine | 1 | 2004 | 102 | 0.250 |
Why?
| | Transgenes | 1 | 2004 | 174 | 0.240 |
Why?
| | Mice, Knockout | 6 | 2022 | 2680 | 0.240 |
Why?
| | Epitopes, T-Lymphocyte | 3 | 2020 | 170 | 0.230 |
Why?
| | Imidazolines | 1 | 2022 | 3 | 0.220 |
Why?
| | Humans | 19 | 2023 | 118972 | 0.210 |
Why?
| | HLA-A2 Antigen | 1 | 2021 | 39 | 0.210 |
Why?
| | Autoimmune Diseases | 2 | 2022 | 398 | 0.200 |
Why?
| | Uveitis | 1 | 2022 | 116 | 0.200 |
Why?
| | Mutation | 3 | 2020 | 3457 | 0.200 |
Why?
| | Nephrotic Syndrome | 1 | 2021 | 33 | 0.190 |
Why?
| | Alleles | 2 | 2021 | 832 | 0.190 |
Why?
| | Podocytes | 1 | 2021 | 57 | 0.190 |
Why?
| | Urinary Tract | 1 | 2020 | 40 | 0.190 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 2 | 2011 | 102 | 0.180 |
Why?
| | Cross Reactions | 1 | 2020 | 116 | 0.180 |
Why?
| | NFATC Transcription Factors | 1 | 2020 | 82 | 0.180 |
Why?
| | HLA-DQ Antigens | 2 | 2019 | 176 | 0.180 |
Why?
| | Forkhead Transcription Factors | 1 | 2020 | 182 | 0.180 |
Why?
| | Genes, Reporter | 1 | 2020 | 270 | 0.170 |
Why?
| | Genotype | 1 | 2004 | 1882 | 0.170 |
Why?
| | Genetic Vectors | 1 | 2020 | 302 | 0.170 |
Why?
| | Tissue Donors | 1 | 2021 | 336 | 0.170 |
Why?
| | Diabetes Mellitus, Experimental | 2 | 2013 | 211 | 0.160 |
Why?
| | Fraser Syndrome | 1 | 2018 | 1 | 0.160 |
Why?
| | Chromogranin A | 1 | 2018 | 40 | 0.160 |
Why?
| | Vesico-Ureteral Reflux | 1 | 2018 | 21 | 0.160 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2021 | 394 | 0.160 |
Why?
| | Immunization | 1 | 2020 | 412 | 0.150 |
Why?
| | Recombination, Genetic | 1 | 2018 | 173 | 0.150 |
Why?
| | Repressor Proteins | 1 | 2020 | 377 | 0.150 |
Why?
| | T-Cell Antigen Receptor Specificity | 3 | 2012 | 41 | 0.150 |
Why?
| | Genetic Variation | 1 | 2021 | 926 | 0.140 |
Why?
| | Kidney Diseases | 1 | 2021 | 439 | 0.140 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 539 | 0.140 |
Why?
| | Mutation, Missense | 1 | 2018 | 300 | 0.140 |
Why?
| | HLA-DR Antigens | 1 | 2016 | 224 | 0.140 |
Why?
| | Young Adult | 3 | 2021 | 10793 | 0.130 |
Why?
| | Child | 5 | 2021 | 19129 | 0.120 |
Why?
| | HLA Antigens | 1 | 2015 | 230 | 0.120 |
Why?
| | Genetic Predisposition to Disease | 2 | 2021 | 2275 | 0.120 |
Why?
| | Mice, Transgenic | 4 | 2009 | 2025 | 0.110 |
Why?
| | DNA-Binding Proteins | 1 | 2020 | 1346 | 0.110 |
Why?
| | Adolescent | 3 | 2021 | 18480 | 0.110 |
Why?
| | Transcription Factors | 1 | 2020 | 1570 | 0.110 |
Why?
| | Complementarity Determining Regions | 1 | 2012 | 45 | 0.110 |
Why?
| | Heterozygote | 2 | 2020 | 262 | 0.100 |
Why?
| | Crosses, Genetic | 2 | 2018 | 138 | 0.100 |
Why?
| | Biomarkers, Tumor | 1 | 2018 | 1059 | 0.100 |
Why?
| | Mice, SCID | 2 | 2018 | 333 | 0.100 |
Why?
| | Homozygote | 2 | 2018 | 190 | 0.100 |
Why?
| | Germ-Line Mutation | 1 | 2012 | 134 | 0.100 |
Why?
| | Organophosphorus Compounds | 1 | 2011 | 76 | 0.100 |
Why?
| | Glycine | 1 | 2011 | 162 | 0.100 |
Why?
| | Female | 7 | 2021 | 61564 | 0.100 |
Why?
| | Antigen Presentation | 1 | 2011 | 194 | 0.090 |
Why?
| | Prediabetic State | 1 | 2013 | 234 | 0.090 |
Why?
| | Adoptive Transfer | 2 | 2013 | 204 | 0.090 |
Why?
| | Major Histocompatibility Complex | 1 | 2010 | 220 | 0.090 |
Why?
| | Immunodominant Epitopes | 1 | 2009 | 27 | 0.090 |
Why?
| | Spleen | 2 | 2013 | 510 | 0.080 |
Why?
| | Amino Acid Sequence | 3 | 2019 | 2071 | 0.080 |
Why?
| | Pedigree | 2 | 2020 | 485 | 0.080 |
Why?
| | Signal Transduction | 1 | 2020 | 4709 | 0.070 |
Why?
| | Poly I-C | 1 | 2005 | 55 | 0.070 |
Why?
| | Male | 5 | 2021 | 57801 | 0.070 |
Why?
| | Ovum | 1 | 2004 | 30 | 0.060 |
Why?
| | Microinjections | 1 | 2004 | 83 | 0.060 |
Why?
| | Disease Progression | 2 | 2018 | 2490 | 0.060 |
Why?
| | Thymus Gland | 2 | 2019 | 300 | 0.060 |
Why?
| | Pancreas | 2 | 2019 | 282 | 0.060 |
Why?
| | Interferon-alpha | 1 | 2005 | 191 | 0.060 |
Why?
| | Conserved Sequence | 2 | 2018 | 219 | 0.060 |
Why?
| | Retinol-Binding Proteins | 1 | 2022 | 13 | 0.060 |
Why?
| | Oleanolic Acid | 1 | 2022 | 9 | 0.060 |
Why?
| | Models, Biological | 1 | 2010 | 1715 | 0.060 |
Why?
| | Adult | 2 | 2021 | 31512 | 0.050 |
Why?
| | Eye Proteins | 1 | 2022 | 77 | 0.050 |
Why?
| | Gene Expression Regulation | 1 | 2012 | 2445 | 0.050 |
Why?
| | Interleukin-17 | 1 | 2022 | 105 | 0.050 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2022 | 83 | 0.050 |
Why?
| | Time Factors | 1 | 2012 | 6412 | 0.050 |
Why?
| | Amphibian Proteins | 1 | 2020 | 1 | 0.050 |
Why?
| | Morpholinos | 1 | 2020 | 30 | 0.050 |
Why?
| | Xenopus | 1 | 2020 | 104 | 0.050 |
Why?
| | Promoter Regions, Genetic | 1 | 2004 | 1158 | 0.050 |
Why?
| | Models, Molecular | 2 | 2018 | 1435 | 0.050 |
Why?
| | Larva | 1 | 2020 | 213 | 0.040 |
Why?
| | Molecular Docking Simulation | 1 | 2019 | 101 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2022 | 688 | 0.040 |
Why?
| | Antioxidants | 1 | 2022 | 564 | 0.040 |
Why?
| | Specific Pathogen-Free Organisms | 1 | 2018 | 61 | 0.040 |
Why?
| | Actins | 1 | 2021 | 404 | 0.040 |
Why?
| | Lysosomes | 1 | 2019 | 136 | 0.040 |
Why?
| | Cells, Cultured | 2 | 2018 | 4077 | 0.040 |
Why?
| | Consanguinity | 1 | 2018 | 49 | 0.040 |
Why?
| | Urogenital System | 1 | 2018 | 16 | 0.040 |
Why?
| | Clone Cells | 1 | 2018 | 248 | 0.040 |
Why?
| | Protein Domains | 1 | 2019 | 212 | 0.040 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2018 | 372 | 0.040 |
Why?
| | Exons | 1 | 2018 | 307 | 0.040 |
Why?
| | Immune Tolerance | 1 | 2019 | 334 | 0.040 |
Why?
| | Extracellular Matrix Proteins | 1 | 2018 | 133 | 0.040 |
Why?
| | Mice, Inbred C57BL | 3 | 2013 | 4908 | 0.040 |
Why?
| | Family | 1 | 2020 | 585 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2019 | 509 | 0.040 |
Why?
| | Calcium-Binding Proteins | 1 | 2018 | 217 | 0.040 |
Why?
| | Models, Animal | 1 | 2018 | 363 | 0.030 |
Why?
| | Mice, Inbred BALB C | 2 | 2011 | 1206 | 0.030 |
Why?
| | Blood Glucose | 1 | 2005 | 1939 | 0.030 |
Why?
| | Animals, Newborn | 1 | 2018 | 806 | 0.030 |
Why?
| | Cytokines | 1 | 2022 | 1900 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2020 | 3171 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2018 | 814 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2019 | 2851 | 0.030 |
Why?
| | Baculoviridae | 1 | 2011 | 46 | 0.030 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 332 | 0.020 |
Why?
| | Small Molecule Libraries | 1 | 2011 | 80 | 0.020 |
Why?
| | Lymph Nodes | 1 | 2013 | 455 | 0.020 |
Why?
| | Antigens, Bacterial | 1 | 2011 | 116 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 2011 | 522 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 827 | 0.020 |
Why?
| | Epitope Mapping | 1 | 2009 | 49 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2011 | 1085 | 0.020 |
Why?
| | Infant | 1 | 2020 | 8293 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2008 | 176 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2011 | 2871 | 0.020 |
Why?
| | Child, Preschool | 1 | 2020 | 9491 | 0.020 |
Why?
| | Chronic Disease | 1 | 2008 | 1636 | 0.010 |
Why?
| | Gene Expression | 1 | 2005 | 1489 | 0.010 |
Why?
| | Aging | 1 | 2005 | 1670 | 0.010 |
Why?
|
|
Nakayama's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|